Health & Biotech SKN delivers hundreds of thousands of litres of its Covid-killing, plant-based, TGA-backed ‘SuprCuvr’ as latest deal pays off March 17, 2022 Special Report: Skin Elements’ distribution deal with Pacific Health Care is off to a massive start with strong sales and… Check Up: Gloomy days for biotechs, but there were significant moves on the ASX this week March 17, 2022 In February 2021, the biotech market was trading at peak levels as the world grappled with the biggest and most… Singular’s additive manufacturing investment is bearing fruit March 16, 2022 Special Report: Singular Health’s (ASX:SHG) investment in additive manufacturing company Additive Engineering is starting to pay off with AE’s facility… PharmAust ships first batch of MPL to the US, gets ready for two upcoming clinical trials March 15, 2022 Special Report: The production of its own monepantel (MPL) drug means that PharmAust is now ready to commence human clinical… ASX Health Stocks: Clinuvel reveals study results, and Cann’s Mildura cannabis facility is a go March 15, 2022 Clinuvel releases positive preliminary results from pilot study Cann's Mildura cannabis facility is ready Imugene signs deal with Merck Respiri… Grey matters: Osteopore shares rise on Singular opportunity to improve cranial implants through AI March 14, 2022 Special Report: Osteopore is getting collaborative with Singular Health, the two med-techs collating data which OSX hopes may lead to… Singular’s AI-based cranial implant gets a partner to dream of in Osteopore March 14, 2022 Special Report: Singular will work with Osteopore to validate an AI-based model for cranial implant design that was developed by… ASX Health Stocks: US FDA approval could expand EBR Systems’ addressable market by $400m March 14, 2022 US FDA approves EBR's wireless pacemakers Singular Health and Osteopore to pursue US FDA and TGA approvals Virtus Heath to… Dr Boreham’s Crucible: Mayne focuses on razzle-dazzle as oral contraceptive approaches the stage March 12, 2022 When it comes to analysing company results, interpretations can differ as widely as Russian news agent Pravda’s reporting of the… ASX Health Stocks: Neuroscientific announces breakthrough as Neuren gets ready for Phase 2 trial March 11, 2022 The ASX 200 Health Index (XHJ) is down by 1.40% at the time of writing, compared to the broader index… Next» « Previous